On May 13, 2020 Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) reported the financial results and corporate updates for the first quarter 2020 (Press release, Evotec, MAY 13, 2020, View Source;announcements/press-releases/p/evotec-se-reports-first-quarter-2020-results-and-provides-corporate-update-5939 [SID1234557960]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

HIGHLIGHTS

STRONG PERFORMANCE IN BASE BUSINESS; INCREASED REVENUES DESPITE MODEST MILESTONE CONTRIBUTIONS IN Q1
15% increase in group revenues from contracts with customers to € 119.4 m (Q1 2019: € 103.8 m)
Strong revenue growth in both segments: EVT Execute revenues up 18% to € 118.2 m (Q1 2019: € 100.3 m), EVT Innovate revenues up 24% to € 23.3 m (Q1 2019: € 18.8 m)
Stable adjusted Group EBITDA of € 30.0 m (Q1 2019: € 30.0 m); adjusted EBITDA of € 35.4 m for EVT Execute (Q1 2019: € 32.2 m)
Increased commitment into unpartnered R&D with expenses of € 11.4 m (Q1 2019: € 8.1 m)
Continued strong strategic liquidity position of € 320.7 m (31 December 2019: € 320.0 m)
No material impact by COVID-19 pandemic on financial development so far

EVT EXECUTE & EVT INNOVATE – STRONG PERFORMANCE AND STRATEGIC POSITION IN BOTH BUSINESS SEGMENTS
Important step into gene therapy with Evotec GT and multi-year gene therapy research alliance with Takeda
New and extended drug discovery and development agreements in EVT Execute (e.g. Amgen, Ildong)
Just – Evotec Biologics on track for success: Strengthened position through first strategic J.POD partnership with MSD and continued good construction progress of the first J.POD facility in Seattle
Advancement of an additional endometriosis programme into clinical Phase I within Bayer alliance, triggering a € 2 m milestone payment
Strengthening of Evotec’s iPSC-based cell therapy platform EVOcells through licensing agreement with panCELLa
Regaining global rights on iPSC-based beta cell replacement therapy from Sanofi and initiation of EVT Innovate initiative QRbeta Therapeutics (after period-end)
Strategic equity investment and partnership with leon-nanodrugs expands formulation platform
Evotec contributing to selected global initiatives to fight Tuberculosis and COVID-19

GUIDANCE FOR FULL-YEAR 2020 CONFIRMED
Unchanged business outlook, taking into account currently visible negative COVID-19 effects
Total group revenues expected to range from € 440 – 480 m (2019: € 446.4 m)
Adjusted Group EBITDA expected to be in the range of € 100 – 120 m (2019: € 123.1 m)
Unpartnered Group R&D expenses of approx. € 40 m

More detailed information and financial tables are available in our Quarterly Statement Q1 published on the Evotec website under the following link: View Source

Webcast/Conference Call
The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance in the reporting period. Furthermore, the Management Board will present an outlook for fiscal year 2020. The conference call will be held in English.

Conference call details

Date: Thursday, 14 May 2020

Time: 02.00 pm CEST (08.00 am EDT, 01.00 pm BST)

A simultaneous slide presentation for participants dialling in via phone is available at View Source

Webcast details

To join the audio webcast and to access the presentation slides you will find a link on our home page shortly before the event.

A replay of the conference call will be available for seven days after the conference and can be accessed in Europe by dialling +49 69 20 17 44 221 (Germany) or +44 20 3364 5150 (UK) and in the USA by dialling +1 844 307 9362. The access code is 315586222#. The on-demand version of the webcast will be available on our website under View Source

On May 13, 2020 BerGenBio ASA (OSE: BGBIO), reported that it will announce its results for the first quarter 2020 on Tuesday 19 May 2020. A webcast presentation by BerGenBio’s senior management team will take place at 10 am CET (Press release, BerGenBio, MAY 13, 2020, View Source [SID1234557957]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will webcast live and the link will be available at www.bergenbio.com in the section Investors/Financial Reports. A recording will be available shortly after the webcast has finished.

The results report and presentation will be available at www.bergenbio.com in the section: Investors/Financial Reports from 7:00 am CET the same day.

On May 13, 2020 Sosei Group Corporation ("the Company"; TSE: 4565) reported its consolidated results for the first quarter ended 31 March 2020 (Press release, Sosei, MAY 13, 2020, View Source [SID1234557956]). The full report can be accessed by clicking here.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Operational Highlights for Q1 2020

Strategy refocused and UK R&D organization realignment complete – strengthened focus on the execution of the next stage of growth strategy, which aims to leverage world-class Platform, Discovery and Early Development capabilities to advance and extend portfolio of Partnered Programs – presented at Annual General Meeting.
New appointments and promotions – Mr. Rolf Soderstrom was appointed as a new Board Director and Dr. Malcolm Weir was promoted to Executive Vice Chairman. Further promotions were made across the organization as part of the UK R&D realignment.
High-impact publication in Nature Reviews Drug Discovery – highlighting potential of structure-based approaches to generate peptide drugs targeting G protein-coupled receptors (GPCRs).
Excellent scientific progress made with orexin agonist program in conjunction with spin-off companies Orexia and Inexia – unique orexin modulator drug discovery and design engine assembled based on structural detail – triggered next tranche of funding from Medixci.
Measures put in place in response to COVID-19 pandemic – policies and practises have been rapidly implemented to ensure safety of employees and other stakeholders and to reduce the spread of coronavirus, while also prioritizing revenue-generating work for our major collaboration partners.
Post-period Highlights

New COVID-19 R&D program launched – multidisciplinary team created to apply world-leading structure-based drug design capabilities to the global research efforts to discover drugs targeting the SARS-CoV-2 coronavirus and to treat COVID-19, also considering future variants of SARS-CoV-2.
Enerzair Breezhaler (QVM149) recommended for approval in European Union as a maintenance treatment of uncontrolled asthma in adult patients – QVM149 is an investigational once-daily, potential first-in-class inhaled LABA/LAMA/ICS combination for asthma patients, in which Sosei Heptares has an economic interest. It is being developed by Novartis and currently under review in Europe, Japan and Canada, among other countries.
Further scientific progress made with orexin agonist program in conjunction with Orexia and Inexia – small molecule agonist bound orexin OX2 receptor solved and small molecule binding site identified – structure determined at significantly higher resolution than previously achieved and expected to provide improved insights to help optimize the discovery and development of novel molecules targeting neurological diseases.
Financial Highlights for the Three-month Period ended 31 March 2020

Revenue totalled JPY 1,162 million (US$10.7 million*) (a decrease of JPY 1,974 million (US$17.8 million) vs. the prior corresponding period), and was primarily related to (i) the absence of upfront payments from new business development deals, and (ii) no major milestone payments from existing collaborations. The timing of new business development deals and progress related to existing programs can vary considerably from quarter to quarter, and the Company expects to achieve new upfronts and milestone payments later in the fiscal year. The prior corresponding period included a one-off US$15 million major milestone payment from AstraZeneca.
Cash R&D expenses were strongly managed and totalled JPY 557 million (US$5.1 million) (a decrease of JPY 379 million (US$3.4 million) vs. the prior corresponding period), primarily related to the Company’s strategic decision to prioritize specific projects as a result of the COVID-19 outbreak.
Cash G&A expenses totalled JPY 437 million (US$4.0 million) (a decrease of JPY 120 million (US$1.0 million) vs. the prior corresponding period), and was primarily related to a reduction in our UK National Insurance liability linked to share-based payments as a result of the reduction in the Company’s share price over the quarter.
Cash profit** totalled JPY 12 million (US$0.1 million) vs. a cash profit of JPY 1,432 million (US$13.0 million) in the prior corresponding period. The main reason for the decrease was due to the decrease in revenue as stated above.
Net loss totalled JPY 746 million (US$6.9 million) vs. a net profit of JPY 1,018 million (US$9.2 million) in the prior corresponding period. The main reason for the net loss was due to the decrease in revenue as stated above.
The Company remains well capitalized, with cash at hand of JPY 16,335 million (US$150.0 million) as at 31 March 2020. The Company’s cash balance increased by approximately JPY 960 million (US$8.8 million) as a result of milestones received from Pfizer and UK tax refunds.
*Convenience conversion to US$ at the following rates: 2020: 1US$ =108.907 JPY; 2019: 1US$ =110.226 JPY

**Non-IFRS measure

Shinichi Tamura, Chairman, President and CEO of Sosei Heptares, commented: "Our operating environment has changed dramatically in recent months as a result of the SARS-CoV-2 pandemic. I am very pleased to report that the company has responded extremely well to these changes by rapidly implementing practises to keep our staff, and other parties with whom we interact, safe and prevent any further spread of the virus; this is our main priority. The measures we have put in place have also ensured a high level of business continuity and enabled us to work on revenue-generating collaborations and other areas of key importance to our business. I am impressed with and extremely grateful to our staff for the level of dedication and commitment they have shown, which has allowed them to deliver outstanding results and scientific achievements in these unprecedented circumstances."

On May 13, 2020 Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, reported that it will webcast a live presentation at the UBS Virtual Global Healthcare Conference on Monday, May 18, 2020 at 12:50 p.m. PT (3:50 p.m. ET) (Press release, Natera, MAY 13, 2020, View Source [SID1234557955]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mike Brophy, Chief Financial Officer, will provide an overview of the company and discuss recent business activities.

Access to the live webcast and subsequent archived presentation will be available at investor.natera.com.

On May 13, 2020 Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) reported that Executive Chairman Robert J. Coury and President Rajiv Malik will present at the 2020 RBC Capital Markets’ Virtual Global Healthcare Conference on Tuesday, May 19, 2020 at 8 a.m. ET (Press release, Mylan, MAY 13, 2020, View Source [SID1234557954]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interested parties can access a live webcast of the presentation via the investor relations section of Mylan’s website at investor.mylan.com. An archived version also will be available following the live presentation and can be accessed at the same location for a limited time.